Hormonioterapia de reposiçäo e câncer de mama

Freitas, Fernando Monteiro de; Menke, Carlos Henrique; Guedes, Ernesto Amaro; Osório, Maria Celeste Wander.
Reprod. clim ; 10(1): 16-20, jan.-mar. 1995. ilus
Artigo em Português | LILACS | ID: lil-163320

Documentos relacionados

  1. My best case: homeopathic management of adverse effects of tamoxifen.
  2. Ovarian Suppression: Early Menopause and Late Effects.
  3. Clinical practice to address tamoxifen nonadherence.
  4. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.
  5. [Ocular toxicity induced by tamoxifen: an overview].
  6. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
  7. Tamoxifen induced hands deformities.
  8. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
  9. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
  10. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.